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Introduction: To evaluate the long-term efficacy and safety of 3 commercially available fixed 
combinations of prostaglandin analogs or a prostamide with timolol maleate in patients with 
primary open angle glaucoma or ocular hypertension.
Methods: In this randomized, prospective, single-blind study, intraocular pressure (IOP) was 
measured after a 1-month washout period and pachymetry was performed before randomizing 
patients to latanoprost 50 µg/timolol 5 mg/1 mL (L/T), bimatoprost 300 µg/timolol 5 mg/1 mL 
(B/T), or travoprost 40 µg/timolol 5 mg/1 mL (T/T). IOP was measured monthly for 6 months 
and then at 12 months by an investigator blinded to the study drug. Adverse reactions were 
recorded.
Results: 128 cases were included in the study. The 3 treatment groups had similar baseline 
characteristics and comparable IOP. All 3 combinations decreased IOP by at least 6 mmHg 
and IOP remained below 21 mmHg throughout the study. At 12 months L/T achieved greater 
  reduction in IOP than the other 2 fixed combinations, but the difference between L/T and 
B/T was not statistically significant. At 6 months, more B/T-treated patients reported red eye 
(P , 0.05 vs L/T and T/T). At 12 months, fewer adverse reactions were reported, with no cases 
of red eye reported for L/T (P = 0.03 vs B/T).
Conclusions: All 3 combinations are effective at lowering IOP but at 12 months L/T and B/T 
were found to be more effective than T/T. Treatments were well tolerated after 12 months but 
L/T showed less hyperemia than B/T throughout the study (P , 0.05).
Keywords: bimatoprost/timolol, fixed combinations, intraocular pressure, latanoprost/timolol, 
ocular hypertension, primary open angle glaucoma, travoprost/timolol.
Introduction
The term glaucoma covers a group of chronic optical neuropathies in which ganglion 
cell damage is associated with a loss of visual field.1 Many patients with ocular hyper-
tension will develop glaucoma.2–4 As high intraocular pressure (IOP) is one of the 
most important risk factors for glaucoma,1–6 most treatments focus on reducing IOP. 
Trabeculectomy7 and laser trabeculoplasty8 have been the main, nonpharmacological 
therapeutic options, but these procedures have potential side effects.
As an alternative, a number of different drugs have become available over the last 
3 decades; the β-blocker timolol was introduced in the late 1970s.9 Prostaglandin ana-
logs were introduced in the late 1990s10 and have proved to be more effective at lowering 
IOP than β-blockers.11,12 More recently, fixed combinations of these agents have been 
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was approved in April 2002.13–15 In October 2006, 2 further 
combinations were approved: travoprost/timolol (travoprost 
40 µg and timolol 5 mg/1 mL)16 and bimatoprost/timolol 
(bimatoprost 300 µg and timolol 5 mg/1 mL).17
Since few data are available comparing the effective-
ness and safety of some of these combinations,18,19 and no 
study has compared the 3 available fixed combinations of 
prostaglandins and timolol, we conducted a 12-month ran-
domized study to compare the hypotensor effect of these 
3 combinations and their tolerability in terms of local events 
reported by patients with primary open angle glaucoma or 
ocular hypertension who had used more than 1 antiglaucoma 
drug previously.
Patients and method
Participants
Patients were eligible for participation in the study if they met 
the following inclusion criteria: age $18 years, primary open 
angle glaucoma or ocular hypertension (IOP $ 21 mmHg at 
baseline), and previously treated with at least 2 hypotensor 
drugs. Exclusion criteria were known contraindication to any 
of the study treatments, use of any medicine that might affect 
IOP, abnormal ocular condition or symptom preventing the 
patient from entering the study according to the investiga-
tor’s judgment, and pregnancy or lactancy. The sample was 
recruited from outpatients attending the “Centre d’Atenció 
Primaria Manso” in Barcelona, Spain. All participants 
signed the informed consent before any study procedures 
were conducted.
Patients were assigned to medical interventions at ran-
dom once we tested that patients fulfilled all the selection 
criteria of the study. Random codes were obtained by means 
of a computerized algorithm after the study protocol and 
related documents were approved by the Scientific Research 
  Committee of the site.
The algorithm produced a block of 9 codes for patients 
allowing a balanced distribution 1:1:1 of study subjects to 
the 3 medical interventions evaluated. Eyes from the same 
patients always received the same medical intervention.
In order to evaluate IOP reduction at 12 months with 
the 3 commercially available fixed combinations, it was 
estimated that 111 cases that met all inclusion criteria and 
none of the exclusion criteria should be included, 37 in each 
treatment arm.
A sample of 37 cases per treatment arm allowed the 
detection of a reduction $2 mmHg with a significance level 
of 95%, power of 80,0%, in bilateral contrast, assuming a 
common standard deviation of 4.
interventions
After a 1-month washout period without any antiglaucoma 
drugs, the patients were randomized to 1 of the 3 combination 
treatments: latanoprost 50 µg and timolol 5 mg/1 mL (L/T); 
travoprost 40 µg and timolol 5 mg/1 mL (T/T); or bimato-
prost 300 µg and timolol 5 mg/1 mL (B/T). These treatments 
were administered at night according to the labeling. Prior 
to treatment, baseline pachymetry was undertaken with the 
DHG 5100E pachymeter and IOP was measured by Goldman 
applanation tonometry.
Evaluations were carried out every month by the same 
masked observer until month 6 and then at month 12. The 
patients were aware of the treatment that they used. All the 
examinations were performed between 8:00 and 10:30 am. 
IOP was measured and patients were asked about side effects 
and adverse events. The primary efficacy variable of the study 
was mean change in IOP between baseline and month 12.
statistical analyses
The primary efficacy variable was IOP reduction with the 
3 commercially available fixed combinations.
Baseline patient characteristics are described using mean 
(SD) values for quantitative variables; absolute and relative 
frequency distributions were used for qualitative variables. 
The Kolmogorov–Smirnov test was used to test for normal 
distribution. Reductions in IOP in follow-up visits are 
expressed in absolute and relative changes versus the baseline 
value in each study group.
The changes from baseline in IOP were calculated using 
measurements of central tendency (mean) and dispersion 
(95% confidence interval [CI]). Groups were compared by 
analysis of variance (ANOVA) and t tests for independent 
samples.
Results
Of the initial group of 141 cases, 13 were excluded because 
of extremely high initial IOP (3 cases in the B/T group), 
very high pachymetry values (2 cases in T/T group and 2 in 
B/T group), poor control of IOP (2 cases in the T/T group), 
substantial discomfort reported by the patient (2 cases 
in the L/T group), and fear of adverse effects of timolol 
maleate (2 cases in the B/T group). Thus, 128 cases com-
pleted the 12 months of follow-up (44 in the T/T group, 42 in 
the B/T group, and 42 in the L/T group).
The mean age of the overall sample was 68 years (range, 
39–88 years). The ANOVA test was 0.064. The mean ages 
of patients in the individual treatment groups were similar, 
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in the B/T group. Overall, 68% were women as a result of 
simple random sampling (50% in the T/T group, 69% in the 
B/T group, and 85% in the L/T group), and there were no 
statistically significant differences between groups. The most 
frequently used prior treatment was L/T and a combination 
of latanoprost and dorzolamide/timolol. The most common 
comorbidities were cataracts (72% in the T/T group, 55% 
in the B/T group, and 71% in the L/T group), hypertension 
(54% in the T/T group, 52% in the B/T group, and 42% in the 
L/T group), and dyslipidemia (46% in the T/T group, 23% 
in the B/T group, and 31% in the L/T group). The only other 
underlying diseases present in more than 20% of patients 
in a given group were diabetes (23% in the L/T group) and 
myopia (21% in the L/T group).
intraocular pressure
The initial IOP, after 1 month without any hypotensive 
drugs (washout period), was between 26 and 28 mmHg 
(26.4 mmHg for T/T, 27.6 mmHg for L/T, and 28.0 mmHg 
for B/T) and showed no significant differences between 
groups (P = 0.22, ANOVA). After 1 month of treatment, 
IOP decreased below 21 mmHg for all combinations 
(Figure 1), and remained below 21 mmHg throughout 
follow-up.
By month 12 significant IOP reductions were observed in 
all the 3 treatment groups. However, mean change from base-
line was significantly greater with L/T and with B/T than with 
T/T; by month 12 the mean IOP reduction was 9.02 mmHg 
for patients treated with L/T, 8.56 mmHg for B/T-treated 
patients, and 6.61 mmHg for patients receiving T/T.
The mean IOP reductions throughout the period of the 
study are summarized in Table 1.
The relative decrease in IOP at month 12 was 26.24% 
for T/T, 30.19% for B/T, and 32.35% for L/T.
Local adverse events
In all treatment groups, the most frequently reported adverse 
event at 6 months was red eye (22.7% [SD 0.4] in the T/T group, 
45.2% [SD 0.5] in the B/T group, and 23.8% [SD 0.4] in the 
L/T group), and the differences between B/T and L/T and T/T 
were statistically significant (P = 0.027 vs T/T and P = 0.039 
vs L/T). Dryness was reported in 22.7% (SD 0.4) of patients 
in the T/T group, 14.1% (SD 0.4) in the L/T group, and 9.5% 
(SD 0.3) in the B/T group; itching by 13.6% (SD 0.3) in the 
T/T group, 16.7% (SD 0.4) in the B/T group, and 14.3% (0.4) 
in the L/T group; and dark eye rings by 4.5% in the T/T group, 
14.3% in the B/T group, and none in the L/T group. No other 
local adverse reaction was reported by more than 10% in a 
given treatment group (Figure 2).
At 12 months, for all 3 combinations, the proportion of 
patients with such symptoms had decreased except for dark 
eye rings, which increased in the T/T group to 13.6% and in 
the L/T group to 15.0%. Of particular note was the decrease 
in red eye in the B/T group from 45.2% at 6 months to 9.5% 
(SD 0.3) at 1 year and the complete absence of red eye in 
the L/T group at 1 year. Despite this decrease, the differ-
ences between B/T and L/T remained statistically significant 
(P = 0.030).
Discussion
Although there are other risk factors associated with the 
development and progression of glaucoma besides IOP, 
the most widely studied and most important risk factor 
is IOP.1,3,6 This is also a factor that can be readily modi-
fied by pharmacological intervention. Different studies 
associate high IOP with damage to the optic nerve and 
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Figure 1 Changes in intraocular pressure (iOP) from baseline.
Abbreviations:  B/T,  bimatoprost/timolol  fixed  combination;  L/T,  latanoprost/
timolol fixed combination; T/T, travoprost/timolol fixed combination; IOP, intraocular 
pressure.
Table 1 group comparisons for absolute decrease in intraocular
Pressure during follow-up
Baseline IOP (mmHg)
T/T  B/T  L/T
Baseline iOP 26.4 28.0 27.6
Decrease in IOP in mmHg (SD)
T/T B/T L/T
Month 1 -6.56 (3.17) -8.88 (3.79)** -7.73 (4.56)
Month 2 -6.36 (2.67) -8.61 (4.47)** -7.88 (4.62)
Month 3 -6.50 (3.66) -8.69 (4.24)* -8.31 (4.57)†
Month 4 -6.59 (3.57) -8.78 (4.71)* -7.55 (4.70)
Month 5 -6.64 (3.06) -8.83 (4.38)** -7.37 (4.72)
Month 6 -6.83 (3.19) -8.71 (4.28)* -8.27 (4.56)
Month 12 -6.61 (2.46) -8.56 (3.70)* -9.02 (3.63)‡
Notes: *P , 0.05; **P , 0.01 T/T vs B/T; †P , 0.05; ‡P , 0.01 T/T vs L/T; not 
significant if not indicated.
Abbreviations: SD, standard deviation; T/T, travoprost/timolol fixed combination; 
B/T, bimatoprost/timolol fixed combination; L/T, latanoprost/timolol fixed combination; 
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Dovepress 
Dovepress
190
Rigollet et al
suggest that the onset of glaucoma is delayed and the 
severity reduced when IOP is reduced.2,4 It has been shown 
that 9.5% of patients with ocular hypertension (defined 
as IOP between 24 mmHg and 32 mmHg in one eye and 
between 21 mmHg and 32 mmHg in the other eye) are at 
risk of developing   glaucoma, but this percentage falls to 
4.4% if these patients are   treated.3 Although the target IOP 
suggested in the Advanced   Glaucoma Intervention Study 
is 18 mmHg,2 the European Glaucoma Society suggests 
that target IOP should be set so as not to damage the optic 
nerve.20
IOP is determined largely by the balance between 
production of aqueous humor and outflow.21 Most of the 
agents currently available act by increasing uveoscleral 
outflow of aqueous humor, as is the case of prostaglandin 
analogs,22 by decreasing production of aqueous humor by the 
ciliary body, as is the case of β-blockers,23 or both, as is the 
case of alpha2-adrenergic agonists such as brimonidine.24 
The clinical efficacy of such substances in lowering IOP has 
been shown in a number of studies. Nevertheless, the targets 
for IOP lowering are quite stringent and may not be reached 
using a single agent.25 In this case, the idea of combining 
2 agents is an attractive one, particularly if they work by 
different mechanisms as is the case of combinations of prosta-
glandins and β-blockers. Studies that compared combinations 
of latanoprost and timolol suggested that there was indeed 
an additive effect and lower IOP could be attained by such 
a strategy.26 With the concept of combined therapy proven, 
it might also be expected that fixed combinations of these 
drugs, which can be applied in a single application, would 
improve the convenience of dosing and so improve adherence 
to treatment.27 Although fixed combination treatments have 
been investigated,13–19 studies comparing the efficacy of the 3 
prostaglandins fixed combinations are not available. Studies 
have however been conducted comparing fixed combination 
timolol/dorzolamide with a combination of timolol with 
unoprostone.28 That study reported similar efficacy for the 
timolol/carbonic anhydrase inhibitor combination and the 
timolol/prostaglandin combination.
Our study aimed to assess the reduction in IOP with 3 
commercially available fixed combinations for lowering 
IOP, namely L/T (latanoprost 50 µg and timolol 5 mg/1 mL), 
T/T (travoprost 40 µg and timolol 5 mg/1 mL), and B/T 
(bimatoprost 300 µg and timolol 5 mg/1 mL). The absolute 
decreases in IOP from baseline were similar to those reported 
in a study with the fixed combination of T/T (7–9 mmHg).16 
We also recorded local adverse reactions given that the tol-
erability is important for ensuring adherence to medication, 
particularly in the case of long-term therapy required to treat 
chronically elevated IOP.
The 3 combinations were good depressors of the IOP and 
all achieved substantial reductions in the IOP.   However, at 
6 months, there were differences in the symptoms reported: 
red eye, dark eye rings, and itching were reported more 
often in the B/T group whereas dryness was reported 
more frequently in the T/T group. After 1 year of follow-up, 
the overall rate of adverse reactions decreased. Thus red eye 
decreased in all groups, and in the L/T group, no patients 
reported this symptom.
These results from 1 year of follow-up support the long-
term efficacy of these fixed combinations. The absolute 
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Figure 2 Reported symptoms at 6 and 12 months for the 3 fixed combinations: 
A) red eye; B) itching; C) dryness.
Abbreviations: T/T, travoprost/timolol fixed combination; B/T, bimatoprost/timolol 
fixed combination; L/T, latanoprost/timolol fixed combination; m, months.Clinical Ophthalmology
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decrease in IOP at 12 months was significantly larger for 
the L/T and B/T combinations than the T/T combination. 
For most symptoms, tolerance improved from 6 to 12 months. 
In particular, the number of patients with red eye decreased 
substantially to such an extent that, for the L/T fixed com-
bination, no patients reported this condition. This suggests 
that these fixed combinations are well tolerated with the 
long-term use required in these patients.
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